|
O.V. Zelenova
Federal Research Institute for Health Organization and Informatics of
Ministry of Health and Social Development of the Russian Federation,
Moscow
Summary. The first trial in Russia. Analysis of
threshold willingness-to- pay for quality adjusted life year in Russia
is a very urgent and serious matter. Methods of willingness-to- pay
investigation are different for various countries and depend on
development of Health Care system. We have estimated willingness-to- pay
method of Contingent valuation and proved that the results vary from
other countries. Submitted data shows payment dedications and demands of
our people for goods and services in medical care.
We have held the opinion poll to define the willingness to pay for quality adjusting life year. Average willingness-to- pay self and willingness-to- pay self5 are rather equal 69 000 and 72 000 rubles (the rub/$ rate in Russia is 30 rub for 1 $). The average willingness-to- pay fam is 16% more than willingness-to- pay self. The fact that willingness-to- pay fam was higher than willingness-to- pay self
suggests that altruistic utility is larger than the respondent’s
perceived value of one QALY gained for themselves, at least in the case
of health care for a family member. Average willingness-to- pay soc is 146 000 rubles that is twice over WTPself5 (72 000 rubles). The fact that willingness-to- pay soc exceeded willingness-to- pay self
may be explained by altruistic motivation in people who were led to
offer a healthcare payment to individuals in need. WTP value is
increasing sequentially from willingness-to- pay self to willingness-to- pay soc
in each category of questionnaire. The main factors which had huge
impact are occupation, age and education. Whereas factors such as
gender, hospitalization (within the last 5 years) and hospitalization of
any member of household (within the last 5 years) didn`t played an
important role.
Key words: Willingness to Pay, threshold, Quality Adjusted Life Year, Incremental cost-effectiveness ratio.
References
- Alekhina G.A. Klassifikatsiya osnovnykh kontseptsiy otsenki
chelovecheskoy zhizni [Classification of the basic conceptions for
assessing a person’s life]. Izvestiya Tomskogo politekhnicheskogo universiteta. Ekonomika. 2007;311(6):119-123.
- Baraz V.R. Korrelyatsionno-regressionnyy analiz svyazi pokazateley
kommercheskoy deyatelnosti s ispolzovaniyem programmy Excel.
[Correlation regressive analysis of interrelations between indicators of
business activity with using the Excel program]. Yekaterinburg:
Federalnoye agentstvo po obrazovaniyu GOU VPO «UGTU − UPI», 2005. 102 p.
- Berezin I.C. Marketingovyye issledovaniya. Kak eto delayut v
Rossii. [Marketing study. How it is done in Russia]. Moscow: Vershina.
2005. 432 p.
- Zdravookhraneniye v tsifrakh [Healthcare in figures]. Menedzher zdravookhraneniya 2010;(11):6, 16.
- Sayenko L. Zhurnal Forbes nazval samyye dorogiye lekarstva v mire
[The Forbes magazine named the world most expensive drugs]. RIA
«Novosti». 23.02.2010. [Internet]. [cited 2010 Nov 16]. Available from:
http://www.rian.ru/society/20100223/210436974.html
- Figueras J, McKee M, Lessof S, Duran A, Menabde N. Sistemy
zdravookhraneniya, zdorovye i blagosostoyaniye: Otsenka argumentov v
polzu investirovaniya v sistemy zdravookhraneniya [Healthcare systems,
health and well-being: assessing arguments in favor of investing in
healthcare systems]. WHO. 2008.
- Spisok stran po VVP (PPS) na dushu naseleniya [The List of
countries by Gross domestic product per capita]. Vikipediya. [cited 2011
Sep 12]. Available from:
http://ru.wikipedia.org/wiki/%D0%A1%D0%VF%D0%V8%D1%81%D0%VE%D0%VA_%D1%81%D1%82%D1%80%D0%V0%D0%VD_%D0%VF%D0%VE_%D0%92%D0%92%D0%9F_%28%D0%9F%D0%9F%D0%A1%29_%D0%VD%D0%V0_%D0%V4%D1%83%D1%88%D1%83_%D0%VD%D0%V0%D1%81%D0%V5%D0%VV%D0%V5%D0%VD%D0%V8%D1%8F
- Yagudina R.I., Kulikov A.Yu., Nguyen T. Opredeleniye «poroga
gotovnosti platit» v Rossii, v Yevropeyskikh stranakh i v stranakh SNG
[Evaluation of “a threshold for payment willingness” in Russia, European
countries, and CIS countries]. Farmakoekonomika 2011;4(1):7-11.
- George B, Harris A, Mitchell A. 2001. Cost-effectiveness analysis
and the consistency of decision making: evidence from pharmaceutical
reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001(19):1103-1109.
- Gyrd-Hansen D. Willingness to pay for a QALY. Health Economics. 2003(12):1049-1060.
- How attractive does a new technology have to be to warrant adoption
and utilization? Tentative guidelines for using clinical and economiс
evaluations /Laupacis A, Feeny D, Detsky AS, Tugwell PX. Canadian Medical Association Journal 1992.146:473-481.
- Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1982(1):61-80.
- Value based pricing for NHS drugs: an opportunity not to be missed?
/Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S,
Sculpher MJ. British Medical Journal 2008;336:251-254.
- What is the price of life and why doesn't it increase at the rate of inflation? /Ubel PA, Hirth RA, Chernew ME, Fendrick AM. Archives of Internal Medicine 2003;163:1637-164.
- Willingness to pay for a quality-adjusted life year: in search of a
standard /Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Medical Decision Making 2000;20:332-342.
- Willingness to pay for a quality-adjusted life year: implications
for societal health care resource allocation /King J T, Tsevat J, Lave
JR, Roberts MS. Medical Decision Making 2005;25:667-677.
Views: 21016
|
